Technical Analysis for PROK - ProKidney Corp.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 8.26% | |
Wide Bands | Range Expansion | 8.26% | |
Up 3 Days in a Row | Strength | 8.26% | |
Up 4 Days in a Row | Strength | 8.26% | |
20 DMA Support | Bullish | 9.62% | |
Wide Bands | Range Expansion | 9.62% | |
Up 3 Days in a Row | Strength | 9.62% | |
20 DMA Support | Bullish | 16.96% | |
Earnings Movers | Other | 16.96% | |
Inside Day | Range Contraction | 16.96% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 5 hours ago |
Up 5% | about 5 hours ago |
Rose Above Previous Day's High | about 6 hours ago |
Up 3% | about 6 hours ago |
Up 2% | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/03/2024
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.51 |
52 Week Low | 1.12 |
Average Volume | 783,955 |
200-Day Moving Average | 3.58 |
50-Day Moving Average | 1.84 |
20-Day Moving Average | 2.31 |
10-Day Moving Average | 2.28 |
Average True Range | 0.32 |
RSI (14) | 57.08 |
ADX | 23.45 |
+DI | 23.71 |
-DI | 14.55 |
Chandelier Exit (Long, 3 ATRs) | 2.40 |
Chandelier Exit (Short, 3 ATRs) | 2.40 |
Upper Bollinger Bands | 2.95 |
Lower Bollinger Band | 1.67 |
Percent B (%b) | 0.59 |
BandWidth | 55.54 |
MACD Line | 0.14 |
MACD Signal Line | 0.17 |
MACD Histogram | -0.0269 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.73 | ||||
Resistance 3 (R3) | 2.72 | 2.61 | 2.68 | ||
Resistance 2 (R2) | 2.61 | 2.53 | 2.61 | 2.66 | |
Resistance 1 (R1) | 2.51 | 2.48 | 2.56 | 2.52 | 2.65 |
Pivot Point | 2.40 | 2.40 | 2.42 | 2.40 | 2.40 |
Support 1 (S1) | 2.30 | 2.32 | 2.35 | 2.32 | 2.19 |
Support 2 (S2) | 2.19 | 2.27 | 2.19 | 2.18 | |
Support 3 (S3) | 2.09 | 2.19 | 2.16 | ||
Support 4 (S4) | 2.11 |